European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R.
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation.
Ricci F, Balducci S, Guerrini F, Grassi S, Ciabatti E, Baratè C, Ferreri MI, Giuliani C, Valetto A, Petrini M, Galimberti S.
Clin Hematol Int. 2020 Jul 27;2(3):129-131. doi: 10.2991/chi.k.200714.001. eCollection 2020 Sep.
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials.
Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M, Estey EH, Dombret H, Chevret S, Ifrah N, Cahn JY, Récher C, Chilton L, Moorman AV, Burnett AK.
Lancet Oncol. 2014 Aug;15(9):986-96. doi: 10.1016/S1470-2045(14)70281-5. Epub 2014 Jul 6.
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R.
Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21.
Imatinib.
Lyseng-Williamson K, Jarvis B.
Drugs. 2001;61(12):1765-74; discussion 1775-6. doi: 10.2165/00003495-200161120-00007.
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
Jabbour E, Strati P, Cabrero M, O'Brien S, Ravandi F, Bueso-Ramos C, Wei Q, Hu J, Abi Aad S, Short NJ, Dinardo C, Daver N, Kadia T, Wierda W, Wei Y, Colla S, Borthakur G, Cortes J, Estrov Z, Kantarjian H, Garcia-Manero G.
Am J Hematol. 2017 Apr;92(4):351-358. doi: 10.1002/ajh.24650. Epub 2017 Feb 13.
Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia.
Hanna J, Zabor EC, Albliwi M, El-Asmar J, Nurse DP, Bawwab A, Abuamsha H, Abu-Farsakh Y, Batah H, Rauf A, Nakitandwe J, Bosler DS, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Mukherjee S, Sobecks RM, Advani AS, Carraway HE, Astbury C, Mustafa Ali MK.
Am J Hematol. 2025 Sep;100(9):1577-1589. doi: 10.1002/ajh.70000. Epub 2025 Jul 11.
Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Cojbasić I, Macukanović-Golubović L.
Srp Arh Celok Lek. 2010 May-Jun;138(5-6):305-8. doi: 10.2298/sarh1006305c.
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G.
J Clin Oncol. 2006 Jan 20;24(3):454-9. doi: 10.1200/JCO.2005.03.2011.
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Kantarjian H, Talpaz M, O'Brien S, Giles F, Rios MB, White K, Garcia-Manero G, Ferrajoli A, Verstovsek S, Wierda W, Kornblau S, Cortes J.
Cancer. 2003 May 1;97(9):2225-8. doi: 10.1002/cncr.11381.
